{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T15:27:54Z","timestamp":1770564474234,"version":"3.49.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,11,10]],"date-time":"2021-11-10T00:00:00Z","timestamp":1636502400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,11,10]],"date-time":"2021-11-10T00:00:00Z","timestamp":1636502400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pituitary"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1007\/s11102-021-01193-w","type":"journal-article","created":{"date-parts":[[2021,11,10]],"date-time":"2021-11-10T12:11:53Z","timestamp":1636546313000},"page":"246-257","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Evaluation of acromegaly treatment direct costs with respect to biochemical control and follow-up length"],"prefix":"10.1007","volume":"25","author":[{"given":"Francesco","family":"Cocchiara","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Campana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federica","family":"Nista","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuliana","family":"Corica","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Ceraudo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angelo","family":"Milioto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diego","family":"Criminelli Rossi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianluigi","family":"Zona","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diego","family":"Ferone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5062-9208","authenticated-orcid":false,"given":"Federico","family":"Gatto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,11,10]]},"reference":[{"key":"1193_CR1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI39375","author":"S Melmed","year":"2009","unstructured":"Melmed S (2009) Acromegaly pathogenesis and treatment. J Clin Invest. https:\/\/doi.org\/10.1172\/JCI39375","journal-title":"J Clin Invest"},{"key":"1193_CR2","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-015-0701-2","author":"T Burton","year":"2016","unstructured":"Burton T, Le Nestour E, Neary M, Ludlam WH (2016) Incidence and prevalence of acromegaly in a large US health plan database. Pituitary. https:\/\/doi.org\/10.1007\/s11102-015-0701-2","journal-title":"Pituitary"},{"key":"1193_CR3","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-16-0117","author":"J Dal","year":"2016","unstructured":"Dal J, Feldt-Rasmussen U, Andersen M, Kristensen LO, Laurberg P, Pedersen L, Dekkers OM, Sorensen HT, Jorgensen JO (2016) Acromegaly incidence, prevalence, complications and long-term prognosis: a nationwide cohort study. Eur J Endocrinol. https:\/\/doi.org\/10.1530\/EJE-16-0117","journal-title":"Eur J Endocrinol"},{"key":"1193_CR4","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-018-1630-4","author":"F Gatto","year":"2018","unstructured":"Gatto F, Trifiro G, Lapi F, Cocchiara F, Campana C, Dell\u2019Aquila C, Ferrajolo C, Arvigo M, Cricelli C, Giusti M, Ferone D (2018) Epidemiology of acromegaly in Italy: analysis from a large longitudinal primary care database. Endocrine. https:\/\/doi.org\/10.1007\/s12020-018-1630-4","journal-title":"Endocrine"},{"key":"1193_CR5","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-018-0928-7","author":"M Caputo","year":"2019","unstructured":"Caputo M, Ucciero A, Mele C, De Marchi L, Magnani C, Cena T, Marzullo P, Barone-Adesi F, Aimaretti G (2019) Use of administrative health databases to estimate incidence and prevalence of acromegaly in Piedmont Region. Italy J Endocrinol Invest. https:\/\/doi.org\/10.1007\/s40618-018-0928-7","journal-title":"Italy J Endocrinol Invest"},{"key":"1193_CR6","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-21-0216","author":"S Crisafulli","year":"2021","unstructured":"Crisafulli S, Luxi N, Sultana J, Fontana A, Spagnolo F, Giuffrida G, Ferrau F, Gianfrilli D, Cozzolino A, Cristina De Martino M, Gatto F, Barone-Adesi F, Cannavo S, Trifiro G (2021) Global epidemiology of acromegaly: a systematic review and meta-analysis. Eur J Endocrinol. https:\/\/doi.org\/10.1530\/EJE-21-0216","journal-title":"Eur J Endocrinol"},{"key":"1193_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ecl.2007.10.002","author":"A Ben-Shlomo","year":"2008","unstructured":"Ben-Shlomo A, Melmed S (2008) Acromegaly. Endocrinol Metab Clin N Am. https:\/\/doi.org\/10.1016\/j.ecl.2007.10.002","journal-title":"Endocrinol Metab Clin N Am"},{"key":"1193_CR8","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-017-0797-7","author":"R Pivonello","year":"2017","unstructured":"Pivonello R, Auriemma RS, Grasso LF, Pivonello C, Simeoli C, Patalano R, Galdiero M, Colao A (2017) Complications of acromegaly: cardiovascular, respiratory and metabolic comorbidities. Pituitary. https:\/\/doi.org\/10.1007\/s11102-017-0797-7","journal-title":"Pituitary"},{"key":"1193_CR9","doi-asserted-by":"publisher","DOI":"10.1007\/s11154-019-09506-y","author":"F Gatto","year":"2019","unstructured":"Gatto F, Campana C, Cocchiara F, Corica G, Albertelli M, Boschetti M, Zona G, Criminelli D, Giusti M, Ferone D (2019) Current perspectives on the impact of clinical disease and biochemical control on comorbidities and quality of life in acromegaly. Rev Endocr Metab Disord. https:\/\/doi.org\/10.1007\/s11154-019-09506-y","journal-title":"Rev Endocr Metab Disord"},{"key":"1193_CR10","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-2700","author":"L Katznelson","year":"2014","unstructured":"Katznelson L, Laws ER Jr, Melmed S, Molitch ME, Murad MH, Utz A, Wass JA, Endocrine S (2014) Acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. https:\/\/doi.org\/10.1210\/jc.2014-2700","journal-title":"J Clin Endocrinol Metab"},{"key":"1193_CR11","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-015-0677-y","author":"A Colao","year":"2016","unstructured":"Colao A, Auriemma RS, Pivonello R (2016) The effects of somatostatin analogue therapy on pituitary tumor volume in patients with acromegaly. Pituitary. https:\/\/doi.org\/10.1007\/s11102-015-0677-y","journal-title":"Pituitary"},{"key":"1193_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-018-0058-5","author":"S Melmed","year":"2018","unstructured":"Melmed S, Bronstein MD, Chanson P, Klibanski A, Casanueva FF, Wass JAH, Strasburger CJ, Luger A, Clemmons DR, Giustina A (2018) A consensus statement on acromegaly therapeutic outcomes. Nat Rev Endocrinol. https:\/\/doi.org\/10.1038\/s41574-018-0058-5","journal-title":"Nat Rev Endocrinol"},{"key":"1193_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2014.21","author":"A Giustina","year":"2014","unstructured":"Giustina A, Chanson P, Kleinberg D, Bronstein MD, Clemmons DR, Klibanski A, van der Lely AJ, Strasburger CJ, Lamberts SW, Ho KK, Casanueva FF, Melmed S, Acromegaly Consensus G (2014) Expert consensus document: a consensus on the medical treatment of acromegaly. Nat Rev Endocrinol. https:\/\/doi.org\/10.1038\/nrendo.2014.21","journal-title":"Nat Rev Endocrinol"},{"key":"1193_CR14","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa444","author":"V Bonert","year":"2020","unstructured":"Bonert V, Mirocha J, Carmichael J, Yuen KCJ, Araki T, Melmed S (2020) Cost-effectiveness and efficacy of a novel combination regimen in acromegaly: a prospective, randomized trial. J Clin Endocrinol Metab. https:\/\/doi.org\/10.1210\/clinem\/dgaa444","journal-title":"J Clin Endocrinol Metab"},{"key":"1193_CR15","doi-asserted-by":"publisher","DOI":"10.1007\/s11154-020-09588-z","author":"A Giustina","year":"2020","unstructured":"Giustina A, Barkhoudarian G, Beckers A, Ben-Shlomo A, Biermasz N, Biller B, Boguszewski C, Bolanowski M, Bollerslev J, Bonert V, Bronstein MD, Buchfelder M, Casanueva F, Chanson P, Clemmons D, Fleseriu M, Formenti AM, Freda P, Gadelha M, Geer E, Gurnell M, Heaney AP, Ho KKY, Ioachimescu AG, Lamberts S, Laws E, Losa M, Maffei P, Mamelak A, Mercado M, Molitch M, Mortini P, Pereira AM, Petersenn S, Post K, Puig-Domingo M, Salvatori R, Samson SL, Shimon I, Strasburger C, Swearingen B, Trainer P, Vance ML, Wass J, Wierman ME, Yuen KCJ, Zatelli MC, Melmed S (2020) Multidisciplinary management of acromegaly: a consensus. Rev Endocr Metab Disord. https:\/\/doi.org\/10.1007\/s11154-020-09588-z","journal-title":"Rev Endocr Metab Disord"},{"key":"1193_CR16","doi-asserted-by":"publisher","DOI":"10.5603\/EP.a2018.0080","author":"M Elbaum","year":"2019","unstructured":"Elbaum M, Mizera L, Bolanowski M (2019) The real costs of acromegaly: analysis of different therapies. Endokrynol Pol. https:\/\/doi.org\/10.5603\/EP.a2018.0080","journal-title":"Endokrynol Pol"},{"key":"1193_CR17","doi-asserted-by":"publisher","DOI":"10.1586\/erp.09.17","author":"NR Biermasz","year":"2009","unstructured":"Biermasz NR, Roelfsema F, Pereira AM, Romijn JA (2009) Cost-effectiveness of lanreotide Autogel in treatment algorithms of acromegaly. Expert Rev Pharmacoecon Outcomes Res. https:\/\/doi.org\/10.1586\/erp.09.17","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"1193_CR18","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-16-0623","author":"E Lesen","year":"2017","unstructured":"Lesen E, Granfeldt D, Houchard A, Dinet J, Berthon A, Olsson DS, Bjorholt I, Johannsson G (2017) Comorbidities, treatment patterns and cost-of-illness of acromegaly in Sweden: a register-linkage population-based study. Eur J Endocrinol. https:\/\/doi.org\/10.1530\/EJE-16-0623","journal-title":"Eur J Endocrinol"},{"key":"1193_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.beem.2019.02.001","author":"L Maione","year":"2019","unstructured":"Maione L, Chanson P (2019) National acromegaly registries. Best Pract Res Clin Endocrinol Metab. https:\/\/doi.org\/10.1016\/j.beem.2019.02.001","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"1193_CR20","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa859","author":"C Campana","year":"2020","unstructured":"Campana C, Cocchiara F, Corica G, Nista F, Arvigo M, Amaru J, Rossi DC, Zona G, Ferone D, Gatto F (2020) Discordant GH and IGF-1 results in treated acromegaly: impact of GH cut-offs and mean values assessment. J Clin Endocrinol Metab. https:\/\/doi.org\/10.1210\/clinem\/dgaa859","journal-title":"J Clin Endocrinol Metab"},{"key":"1193_CR21","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-018-0884-4","author":"MJ van Esdonk","year":"2018","unstructured":"van Esdonk MJ, van Zutphen EJM, Roelfsema F, Pereira AM, van der Graaf PH, Biermasz NR, Stevens J, Burggraaf J (2018) How are growth hormone and insulin-like growth factor-1 reported as markers for drug effectiveness in clinical acromegaly research? A comprehensive methodologic review. Pituitary. https:\/\/doi.org\/10.1007\/s11102-018-0884-4","journal-title":"Pituitary"},{"key":"1193_CR22","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-017-0835-5","author":"AJ van der Lely","year":"2017","unstructured":"van der Lely AJ, Gomez R, Pleil A, Badia X, Brue T, Buchfelder M, Burman P, Clemmons D, Ghigo E, Jorgensen JOL, Luger A, van der Lans-Bussemaker J, Webb SM, Strasburger CJ (2017) Development of ACRODAT((R)), a new software medical device to assess disease activity in patients with acromegaly. Pituitary. https:\/\/doi.org\/10.1007\/s11102-017-0835-5","journal-title":"Pituitary"},{"key":"1193_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.677919","author":"F Nista","year":"2021","unstructured":"Nista F, Corica G, Castelletti L, Khorrami K, Campana C, Cocchiara F, Zoppoli G, Prior A, Rossi DC, Zona G, Ferone D, Gatto F (2021) Clinical and radiological predictors of biochemical response to first-line treatment with somatostatin receptor ligands in acromegaly: a real-life perspective. Front Endocrinol (Lausanne). https:\/\/doi.org\/10.3389\/fendo.2021.677919","journal-title":"Front Endocrinol (Lausanne)"},{"key":"1193_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.endonu.2012.09.010","author":"G Sesmilo","year":"2013","unstructured":"Sesmilo G (2013) Epidemiology of acromegaly in Spain. Endocrinol Nutr. https:\/\/doi.org\/10.1016\/j.endonu.2012.09.010","journal-title":"Endocrinol Nutr"},{"key":"1193_CR25","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-17-0253","author":"P Petrossians","year":"2017","unstructured":"Petrossians P, Daly AF, Natchev E, Maione L, Blijdorp K, Sahnoun-Fathallah M, Auriemma R, Diallo AM, Hulting AL, Ferone D, Hana V Jr, Filipponi S, Sievers C, Nogueira C, Fajardo-Montanana C, Carvalho D, Hana V, Stalla GK, Jaffrain-Rea ML, Delemer B, Colao A, Brue T, Neggers S, Zacharieva S, Chanson P, Beckers A (2017) Acromegaly at diagnosis in 3173 patients from the Liege Acromegaly Survey (LAS) Database. Endocr Relat Cancer. https:\/\/doi.org\/10.1530\/ERC-17-0253","journal-title":"Endocr Relat Cancer"},{"key":"1193_CR26","doi-asserted-by":"publisher","DOI":"10.1007\/BF03345306","author":"G Didoni","year":"2004","unstructured":"Didoni G, Grottol S, Gasco V, Battistini M, Ferone D, Giusti M, Ragazzoni F, Ruffo P, Ghigo E, Minuto F (2004) Cost-of-illness study in acromegalic patients in Italy. J Endocrinol Invest. https:\/\/doi.org\/10.1007\/BF03345306","journal-title":"J Endocrinol Invest"},{"key":"1193_CR27","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-17-1006","author":"L Kasuki","year":"2018","unstructured":"Kasuki L, Wildemberg LE, Gadelha MR (2018) MANAGEMENT OF ENDOCRINE DISEASE: personalized medicine in the treatment of acromegaly. Eur J Endocrinol. https:\/\/doi.org\/10.1530\/EJE-17-1006","journal-title":"Eur J Endocrinol"},{"key":"1193_CR28","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-017-0614-1","author":"A Giustina","year":"2017","unstructured":"Giustina A, Arnaldi G, Bogazzi F, Cannavo S, Colao A, De Marinis L, De Menis E, Degli Uberti E, Giorgino F, Grottoli S, Lania AG, Maffei P, Pivonello R, Ghigo E (2017) Pegvisomant in acromegaly: an update. J Endocrinol Invest. https:\/\/doi.org\/10.1007\/s40618-017-0614-1","journal-title":"J Endocrinol Invest"},{"key":"1193_CR29","doi-asserted-by":"publisher","DOI":"10.1007\/BF03346566","author":"A Colao","year":"2010","unstructured":"Colao A, Lombardi G (2010) Dose optimization of somatostatin analogues for acromegaly patients. J Endocrinol Invest. https:\/\/doi.org\/10.1007\/BF03346566","journal-title":"J Endocrinol Invest"},{"key":"1193_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/s12902-017-0199-x","author":"JD Carmichael","year":"2017","unstructured":"Carmichael JD, Broder MS, Cherepanov D, Chang E, Mamelak A, Said Q, Neary MP, Bonert V (2017) Long-term treatment outcomes of acromegaly patients presenting biochemically-uncontrolled at a tertiary pituitary center. BMC Endocr Disord. https:\/\/doi.org\/10.1186\/s12902-017-0199-x","journal-title":"BMC Endocr Disord"},{"key":"1193_CR31","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-16-1064","author":"L Maione","year":"2017","unstructured":"Maione L, Brue T, Beckers A, Delemer B, Petrossians P, Borson-Chazot F, Chabre O, Francois P, Bertherat J, Cortet-Rudelli C, Chanson P, French Acromegaly Registry Group (2017) Changes in the management and comorbidities of acromegaly over three decades: the French Acromegaly Registry. Eur J Endocrinol. https:\/\/doi.org\/10.1530\/EJE-16-1064","journal-title":"Eur J Endocrinol"},{"key":"1193_CR32","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.648411","author":"M Puig-Domingo","year":"2021","unstructured":"Puig-Domingo M, Bernabeu I, Pico A, Biagetti B, Gil J, Alvarez-Escola C, Jorda M, Marques-Pamies M, Soldevila B, Galvez MA, Camara R, Aller J, Lamas C, Marazuela M (2021) Pasireotide in the personalized treatment of acromegaly. Front Endocrinol (Lausanne). https:\/\/doi.org\/10.3389\/fendo.2021.648411","journal-title":"Front Endocrinol (Lausanne)"},{"key":"1193_CR33","doi-asserted-by":"publisher","DOI":"10.1007\/s11154-018-9465-0","author":"S Pedraza-Arevalo","year":"2018","unstructured":"Pedraza-Arevalo S, Gahete MD, Alors-Perez E, Luque RM, Castano JP (2018) Multilayered heterogeneity as an intrinsic hallmark of neuroendocrine tumors. Rev Endocr Metab Disord. https:\/\/doi.org\/10.1007\/s11154-018-9465-0","journal-title":"Rev Endocr Metab Disord"},{"key":"1193_CR34","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-017-0838-2","author":"FF Casanueva","year":"2017","unstructured":"Casanueva FF, Barkan AL, Buchfelder M, Klibanski A, Laws ER, Loeffler JS, Melmed S, Mortini P, Wass J, Giustina A, Pituitary Society, Expert Group on Pituitary Tumors (2017) Criteria for the definition of Pituitary Tumor Centers of Excellence (PTCOE): A Pituitary Society Statement. Pituitary. https:\/\/doi.org\/10.1007\/s11102-017-0838-2","journal-title":"Pituitary"},{"key":"1193_CR35","doi-asserted-by":"publisher","DOI":"10.1111\/cen.12797","author":"MR Gadelha","year":"2015","unstructured":"Gadelha MR (2015) A paradigm shift in the medical treatment of acromegaly: from a \u2018trial and error\u2019 to a personalized therapeutic decision-making process. Clin Endocrinol (Oxf). https:\/\/doi.org\/10.1111\/cen.12797","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1193_CR36","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-017-0849-z","author":"V Bonert","year":"2018","unstructured":"Bonert V, Carmichael J, Wu Z, Mirocha J, Perez DA, Clarke NJ, Reitz RE, McPhaul MJ, Mamelak A (2018) Discordance between mass spectrometry and immunometric IGF-1 assay in pituitary disease: a prospective study. Pituitary. https:\/\/doi.org\/10.1007\/s11102-017-0849-z","journal-title":"Pituitary"}],"container-title":["Pituitary"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-021-01193-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11102-021-01193-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-021-01193-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,3]],"date-time":"2022-03-03T15:12:20Z","timestamp":1646320340000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11102-021-01193-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,10]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["1193"],"URL":"https:\/\/doi.org\/10.1007\/s11102-021-01193-w","relation":{},"ISSN":["1386-341X","1573-7403"],"issn-type":[{"value":"1386-341X","type":"print"},{"value":"1573-7403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,10]]},"assertion":[{"value":"30 October 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no conflicts of interest to declare that are relevant to the content of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving humans and animal rights"}}]}}